Background
Methods
Study population
Biochemical measurements
Ethical considerations
Statistical analysis
Results
HFpEF | HFmrEF | HFrEF | Overall | HFpEF vs. HFmrEF | HFmrEF vs. HFrEF | HFpEF vs. HFrEF | |
---|---|---|---|---|---|---|---|
(n = 51 36.6%) | (n = 39 28.1%) | (n = 49 35.3%) |
P
|
P
|
P
|
P
| |
Characteristic | |||||||
Age, years | 79.3 ± 8.9 | 77.2 ± 10.2 | 78.0 ± 11.8 | 0.553 | 0.297 | 0.626 | 0.501 |
Male gender | 30(58.8%) | 26(66.6%) | 42(85.7%) | <0.001 | <0.05 | <0.001 | <0.001 |
Current smoking | 15(29.4%) | 12(30.7%) | 15(30.6%) | <0.001 | <0.001 | <0.001 | <0.001 |
Hypertension | 33(64.7%) | 28(71.7%) | 40(81.6%) | <0.001 | 0.001 | <0.001 | <0.001 |
Diabetes | 12(23.5%) | 12(30.7%) | 16(32.6%) | <0.001 | <0.001 | 0.001 | <0.001 |
NYHA III/IV | 37(72.5%) | 30(76.9%) | 44(89.7%) | <0.001 | <0.001 | <0.001 | <0.001 |
LVEF(%) | 60.1 ± 6.6 | 44.5 ± 2.9 | 32.6 ± 4.1 | <0.001 | <0.001 | <0.001 | <0.001 |
Weight(kg) | 59.4 ± 10.8 | 60.9 ± 10.2 | 60.0 ± 10.9 | 0.735 | 0.143 | 0.644 | 0.799 |
BMI | 22.7 ± 4.0 | 22.9 ± 3.0 | 22.0 ± 3.2 | 0.791 | 0.654 | 0.775 | 0.526 |
Nt-proBNP | 5825.8 ± 6484.2 | 9664 ± 10,189.1 | 11,248.1 ± 10,875.1 | <0.05 | <0.05 | 0.408 | <0.05 |
Other medical history | |||||||
Coronary heart disease | 41((80.3%) | 29(74.3%) | 39(79.5%) | <0.001 | <0.001 | <0.001 | <0.001 |
Prior revascularization | 10(19.6%) | 7(17.9%) | 17(34.6%) | <0.001 | <0.001 | <0.001 | <0.001 |
Prior myocardial infarction | 6(11.7%) | 9(23%) | 8(16.3) | <0.001 | <0.001 | <0.001 | <0.001 |
Dilated myocardiopathy | 0(0%) | 5(12.8%) | 12(24.4%) | <0.001 | <0.001 | <0.001 | <0.001 |
Atrial fibrillation | 29(56.8%) | 17(43.5%) | 16(32.6%) | 0.203 | 0.833 | <0.05 | 0.317 |
Therapies | |||||||
Diuretics | 39(76.4%) | 38(97.4%) | 42(85.7%) | <0.001 | <0.001 | <0.001 | <0.001 |
Aldosteroneantagonists | 38(77.5%) | 26(66.6%) | 34(69.3%) | <0.001 | <0.001 | <0.05 | <0.001 |
Beta-blockers | 35(68.6%) | 21(53.8%) | 24(48.9%) | 0.075 | <0.05 | 0.831 | 0.072 |
ACEI/ARB | 32(61.5%) | 21(53.8%) | 32(65.3%) | <0.05 | 0.092 | 0.055 | <0.05 |
Digitoxin | 8(15.6%) | 10(25.6%) | 22(44.8%) | <0.001 | <0.001 | <0.05 | <0.001 |
Statins | 34(66.6%) | 28(71.7%) | 33(67.3%) | <0.001 | <0.001 | <0.001 | 0.001 |
Warfarin | 15(29.4%) | 6(15.3%) | 6(12.2%) | <0.001 | <0.001 | <0.001 | <0.001 |
Regression coefficient |
P
| |
---|---|---|
Diabetes | 0.092 | 0.28 |
Hypertension | 0.156 | 0.033 |
Weight | 0.092 | 0.28 |
BMI | 0.151 | 0.076 |
CHD | 0.00004 | 0.713 |
Regression coefficient |
P
| |
---|---|---|
Weight | 0.114 | 0.183 |
BMI | 0.142 | 0.117 |
CHD | 0.097 | 0.459 |
LVEF | −0.229 | 0.004 |
NYHA class | 0.214 | 0.014 |